Cost-effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases

Cancer

Volumn 83, Issue 5, 1998, Pages 882-888

  Durand Zaleski, Isabelle ^a   Earlam, Sally ^b   Fordy, Carol ^b   Davies, Michael ^b   Allen Mersh, Timothy G ^b,c  

^a HENRI MONDOR HOSPITAL   (France)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Colorectal liver metastases; Costs benefit analysis; Hepatic arterial floxuridine; Systemic 5 fluorouracil

Indexed keywords

FLOXURIDINE; FLUOROURACIL; FOLINIC ACID;

ABSENTEEISM; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HUMAN; INFUSION PUMP; INTERMETHOD COMPARISON; LIVER METASTASIS; MAJOR CLINICAL STUDY; PALLIATIVE THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HEALTH CARE COSTS; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032169437     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980901)83:5<882::AID-CNCR12>3.0.CO;2-R     Document Type: Article

References (28)

1. Allen-Mersh TG. Improving survival after large bowel cancer: surgeons should look for the occult. Leader. BMJ 1991; 303:595-6.
2. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced symptomatic colorectal cancer. J Clin Oncol 1992; 10:904-11.
3. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet 1994;344:1255-60.
4. Williams N. Colorectal cancer: epidemiology, aetiology, pathology, clinical features and diagnosis. In: Keighley M, Williams N, editors. Surgery of the anus, rectum and colon. Volume 1. Oxford: W.B. Saunders 1993:830-3.
5. Burke D, Allen-Mersh TG. Investigation and treatment of colorectal liver metastases. Postgrad Med J 1996;72:464-9.
6. Meta-Analysis Group In Cancer. Reappraisal of hepatic arterial infusion in the treatment of non-resectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996;88: 252-8.
7. Fordy C, Burke D, Earlam S, Twort P, Allen-Mersh TG. Treatment interruptions and complications with two continuous hepatic artery floxuridine infusion systems in colorectal liver metastases. Br J Cancer 1995;72:1023-5.
8. Burke D, Earlam S, Fordy C, Allen-Mersh TG. Effect of aberrant hepatic arterial anatomy on tumour response to regional floxuridine infusion for colorectal liver metastases. Br J Surg 1995;82:1098-100.
9. Cole BF. Evaluating the clinical and economic trade-offs of hepatic arterial infusion J Natl Cancer Inst 1996;88:223-4.
10. Drummond M, Stoddart G, Torrance G. Methods for economic evaluation of health care programmes. Oxford: Oxford University Press, 1989:18-83.
11. Drummond M. Allocating resources. Int J Technol Assess Health Care 1990;6:77-92.
12. Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology. A report on principles. Ann Intern Med 1995;122: 61-71.
13. Canadian Coordinating Office for Health Technology Assessment. Guidelines for the economic evaluation of drugs. Ottawa, Ontario, Canada: 1994.
14. International comparison of health care financing and delivery: data and perspectives. 1989 Annual Supplement. Health Care Financing Administration. Baltimore, MD: U.S. Department of Health and Human Services, 1989:192.
15. Robinson R. Costs and cost-minimization analysis. BMJ 1993;307:726-8.
16. Robinson R. Cost-effectiveness analysis. BMJ 1993;307: 793-5.
17. Robinson R. Cost-utility analysis. BMJ 1993;307:859-62.
18. Hsiao W, Braun P, Becker E, Dunn D, Kelly N, Causino N, et al. Results and impact of the resource-based relative value scale. Med Care 1992;30:NS61-79.
19. Latimer E, Becker E. Incorporating practice costs into the resource-based relative value scale. Med Care 1992;30: NS50-60.
20. Earlam S, Glover G, Fordy C, Burke D, Allen-Mersh TG. Relation between tumour size, quality of life and survival in patients with colorectal liver metastases. J Clin Oncol 1996; 1:171-5.
21. Dworkin MJ, Burke D, Earlam S, Fordy C, Allen-Mersh TG. Measurement of response to treatment in colorectal liver metastases. Br J Cancer 1995;71:873-6.
22. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
23. Robinson R. Economic evaluation and health care: what does it mean? BMJ 1993;307:670-3.
24. Drummond M. Cost-effectiveness guidelines for the reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Econ 1992;1:85-92.
25. Earlam S, Glover C, Davies M, Fordy C, Allen-Mersh TG. Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients. J Clin Oncol 1997;15:2022-9.
26. Laupacis A, Feeny D, Detsky A, Tugwell P. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-81.
27. Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993;85:1460-74.
28. Mason J, Drummond M, Torrance G. Some guidelines on the use of cost-effectiveness league tables. BMJ 1993;306: 57-2.